arvedilol or Metoprolol uropou 2006 Trial (COMET) 1511 patients receive carvedilol (25 mg BID); 1518 receive metoprolol (50 mg BID) NYHA II-IV;EF<.35;ACE-I+ diuretic (if tolerated) Mean 58 months in trial Carvedilol reduced all- cause (HR.83)and CV(.80) mortality relative to meto Poole-Wilson.Lancet 2003:362:7-13Carvedilol or Metoprolol European Carvedilol or Metoprolol European Trial (COMET) Trial (COMET)  1511 patients receive carvedilol (25 mg BID); 1518 receive metoprolol (50 mg BID)  NYHA II-IV; EF<.35; ACE-I + diuretic (if tolerated)  Mean 58 months in trial  Carvedilol reduced all￾cause (HR .83) and CV (.80) mortality relative to meto 0 10 20 30 40 All CV Car Met % Poole-Wilson. Lancet 2003;362:7-13 Deaths Deaths